SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Bristol Myers Squibb office in California
Legal
Federal Judge Dismisses $6.4B Lawsuit Against BMS Over Celgene Acquisition
District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol Myers Squibb because it is not a properly appointed trustee for shareholders’ contingent value rights.
October 1, 2024
 · 
1 min read
 · 
Tristan Manalac
3D illustration of human kidneys on a scientific background
Immunology and inflammation
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment
William Blair analyst Matt Phipps in a note to investors wrote that despite the patient deaths, the totality of the data still leans in favor of Kezar Life Sciences’ investigational immunoproteasome inhibitor zetomipzomib.
October 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Johnson & Johnson's business center in Switzerland
Drug pricing
J&J Reverses Course on 340B Rebate Plans Following HRSA Warning
Faced with potential monetary fines, Johnson & Johnson said Monday it is abandoning a proposed 340B rebate plan for hospitals involving two of its blockbuster drugs, Stelara and Xarelto.
October 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Collage illustration of salary negotiation
Career Advice
How to Negotiate Your Salary According to Market Value
In our comprehensive guide to salary negotiation, we’ll teach you what a market salary is, how to research a market value salary and, ultimately, how to negotiate your salary according to market value.
October 1, 2024
 · 
5 min read
 · 
Franklin Carpenter
Fashionable halftone collage. Concept of wealth, saving, saving and saving money. Money bag with dollar stacks and stacks of coins. Vector illustration of business and finance for web banner, social media banner, marketing material. Vector illustration
Weight loss
Kailera Launches With $400M to Advance China-Developed Obesity Assets
Venture Capital firms Atlas Venture, Bain Capital Life Sciences and RTW Investments have led a $400 million Series A for Kailera Therapeutics, the latest obesity biotech to hit the scene.
October 1, 2024
 · 
1 min read
 · 
Annalee Armstrong
3D illustration of tow GLP-1 therapy autoinjectors
GLP-1
Obesity Startup Metsera Inks Manufacturing Pact With Amneal on Heels of Phase I Readout
A week after it released positive early-stage data, Metsera has partnered with Amneal Pharmaceuticals in an effort to secure the development and supply of its investigational weight loss therapy MET-097.
October 1, 2024
 · 
2 min read
 · 
Tristan Manalac
3D concept photo of gene editing showing a tweezers inserting a DNA fragment into a larger strand
Gene Editing
Gene Editor Prime Medicine Signs BMS Cell Therapy Deal, Reprioritizes Pipeline
In an effort to expand its cash runway beyond 12 months, Prime Medicine has signed a deal with Bristol Myers Squibb worth a potential $3.5 billion, while also streamlining its pipeline to trim costs.
September 30, 2024
 · 
2 min read
 · 
Annalee Armstrong
Roche's signage at its office in France
M&A
Roche Doubles Down on Breast Cancer With $850M for Regor’s CDK Inhibitors
The acquisition was featured Monday in Roche’s Pharma Day presentation, which also included projections of more than $3 billion in annual sales from three early-stage obesity and diabetes drugs.
September 30, 2024
 · 
2 min read
 · 
Heather McKenzie
Pictured: MRI images of the brain for neurological
Drug Development
Novartis’ Lutathera Radiopharma Therapy Improves Survival in Difficult-to-Treat Brain Tumors
Six months after treatment with the radiopharmaceutical therapy, 77.8% of patients with meningioma were alive and had not experienced further disease progression, beating the 26% benchmark established in earlier studies.
September 30, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS